PMC:7289100 / 35922-36131 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T442","span":{"begin":112,"end":130},"obj":"Disease"}],"attributes":[{"id":"A442","pred":"mondo_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/MONDO_0005554"}],"text":"Similarly, Conticini et al recently reported of a large cohort of 859 patients from Italy affected by different rheumatic diseases, which were treated by biological DMARDs or by targeted synthetic DMARDs [95]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T270","span":{"begin":48,"end":49},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Similarly, Conticini et al recently reported of a large cohort of 859 patients from Italy affected by different rheumatic diseases, which were treated by biological DMARDs or by targeted synthetic DMARDs [95]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T220","span":{"begin":0,"end":209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Similarly, Conticini et al recently reported of a large cohort of 859 patients from Italy affected by different rheumatic diseases, which were treated by biological DMARDs or by targeted synthetic DMARDs [95]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1188","span":{"begin":70,"end":78},"obj":"Species"},{"id":"1256","span":{"begin":112,"end":130},"obj":"Disease"},{"id":"1257","span":{"begin":187,"end":203},"obj":"Disease"}],"attributes":[{"id":"A1188","pred":"tao:has_database_id","subj":"1188","obj":"Tax:9606"},{"id":"A1256","pred":"tao:has_database_id","subj":"1256","obj":"MESH:D012216"},{"id":"A1257","pred":"tao:has_database_id","subj":"1257","obj":"OMIM:146820"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Similarly, Conticini et al recently reported of a large cohort of 859 patients from Italy affected by different rheumatic diseases, which were treated by biological DMARDs or by targeted synthetic DMARDs [95]."}